AAM Calls on FTC to Investigate PBM Business Practices

Generic Manufacturers Ask the DOJ and the FTC to Investigate Market Abuses by Buying Groups

Seniors Are Still Missing Out on Savings in Medicare Part D

Generic Prices Are Falling, But Seniors Are Paying More for Generic Drugs. What’s Happening Here?

2021 U.S. Generic and Biosimilar Medicines Savings Report

Sidelined: How Seniors Miss Out On Savings Available Through Generic Substitution

Access Denied: Why New Generics Are Not Reaching America’s Seniors

AAM Securing Sustainable Markets

Abuse of the patent system is keeping drug prices high for patients

The Medicaid Generics Penalty: A Primer
